Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
Investor's Business Daily on MSN4d
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...
Viking Therapeutics has seen a significant drop, despite positive news and promising GLP-1 drug developments. Find out why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback